These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29675798)

  • 1. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
    Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
    BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
    Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
    Patel T; Nageeta F; Sohail R; Butt TS; Ganesan S; Madhurita F; Ahmed M; Zafar M; Zafar W; Zaman MU; Varrassi G; Khatri M; Kumar S
    Ann Med; 2023; 55(2):2239830. PubMed ID: 37498865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
    Feng Z; Tong WK; Zhang X; Tang Z
    Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies.
    Wang S; Wang S; Wang Y; Luan J
    Diabetes Ther; 2024 Feb; 15(2):497-519. PubMed ID: 38175486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
    Jabbour S; Paik JS; Aleppo G; Sharma P; Gomez Valderas E; Benneyworth BD
    Endocr Pract; 2024 May; ():. PubMed ID: 38723893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X; Liang Y; Gamble C; King A
    Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in GLP-1 treatment: focus on oral semaglutide.
    Eliaschewitz FG; Canani LH
    Diabetol Metab Syndr; 2021 Sep; 13(1):99. PubMed ID: 34526121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.
    Lee BW; Cho YM; Kim SG; Ko SH; Lim S; Dahaoui A; Jeong JS; Lim HJ; Yu JM
    Diabetes Ther; 2024 Feb; 15(2):547-563. PubMed ID: 38236431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
    Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.
    Wu W; Tong HM; Li YS; Cui J
    Endocrine; 2024 Mar; 83(3):571-584. PubMed ID: 38097902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.
    Orme ME; Nguyen H; Lu JY; Thomas SA
    Diabetes Metab Syndr Obes; 2017; 10():111-122. PubMed ID: 28435304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.
    Holmes P; Bell HE; Bozkurt K; Catarig AM; Clark A; Machell A; Sathyapalan T
    Diabetes Ther; 2021 Nov; 12(11):2891-2905. PubMed ID: 34562237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
    García de Lucas MD; Caballero I; Fernández-García JC; Domínguez-Rodríguez M; Moreno-Moreno P; Jiménez-Millán A; Botana-López M; Avilés B; Merino-Torres JF; Soto A; Tejera C; Morales C
    Front Endocrinol (Lausanne); 2023; 14():1240279. PubMed ID: 37955013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
    Johansen P; Håkan-Bloch J; Liu AR; Bech PG; Persson S; Leiter LA
    Pharmacoecon Open; 2019 Dec; 3(4):537-550. PubMed ID: 30927241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
    Evans M; Berry S; Malkin SJP; Hunt B; Sharma A
    Diabetes Ther; 2023 Jun; 14(6):1005-1021. PubMed ID: 37120480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes.
    Kanai R; Kinoshita S; Kanbe I; Sameda M; Yamaoka S; Horikawa O; Watanabe Y; Tatsuno I; Shirai K; Oshiro T; Saiki A
    Obes Pillars; 2024 Mar; 9():100098. PubMed ID: 38230266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.
    Rana KB; Britnell SR; Gilbertson ME; Ibrahim SL
    J Pharm Pract; 2023 Oct; 36(5):1095-1101. PubMed ID: 35414304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.